Last $45.69 USD
Change Today +0.45 / 0.99%
Volume 868.6K
NVO On Other Exchanges
New York
As of 8:04 PM 08/20/14 All times are local (Market data is delayed by at least 15 minutes).

novo-nordisk a/s-spons adr (NVO) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/25/14 - $48.42
52 Week Low
09/6/13 - $32.20
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NOVO-NORDISK A/S-SPONS ADR (NVO)

Related News

No related news articles were found.

novo-nordisk a/s-spons adr (NVO) Details

Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals. The Diabetes Care segment covers insulins, GLP-1 analog, obesity, and oral antidiabetic drugs, as well as other protein related products comprising glucagon, protein related delivery systems, and needles. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth hormone therapy, hormone replacement therapy, and inflammation. The company sells its products primarily in North America, China, Japan, Algeria, Argentina, Australia, Brazil, India, Turkey, and European countries through its subsidiaries, distributors, and independent agents. Novo Nordisk A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

40,226 Employees
Last Reported Date: 08/7/14
Founded in 1925

novo-nordisk a/s-spons adr (NVO) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: kr15.2M
President and Chief Operating Officer
Total Annual Compensation: kr9.0M
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: kr8.1M
Chief Science Officer and Executive Vice Pres...
Total Annual Compensation: kr8.1M
Chief of Staff and Executive Vice President
Total Annual Compensation: kr7.0M
Compensation as of Fiscal Year 2013.

novo-nordisk a/s-spons adr (NVO) Key Developments

Novo Nordisk Accepts Fine for Violating Disclosure Obligation in Denmark

Novo Nordisk A/S has accepted DKK 500,000 fine imposed by the Public Prosecutor in a suit filed by the Danish Financial Supervisory Authority and detailed in a press release issued by the company on 10 December 2013. In December 2013, the Danish Financial Supervisory Authority reported the company to the police for violating its obligation under Section 27 (1) of the Danish Securities Trading Act to disclose inside information as soon as possible. The reporting concerned the company's receipt of a Complete Response Letter from the US Food and Drug Administration (FDA) in the evening of 8 February 2013. In the letter, the FDA stated that approvals for the insulin products Tresiba and Ryzodeg could not be granted on the basis given. Novo Nordisk published the FDA's decision in a company announcement on 10 February 2013 following an intensive investigation and evaluation of the implications and impact of the agency's decision. In the opinion of the Danish Financial Supervisory Authority and the Public Prosecutor, Novo Nordisk should have issued a company announcement already on the 8 February 2013 evening. Novo Nordisk is of the opinion that the company announcement was issued in a timely manner. The company maintains that even if the disclosure obligation could be said to apply already on the 8 February 2013 evening, the company was entitled to delay public disclosure until the implications of the decision had been adequately analyzed, which they had been on the 10 February 2013. However, for resource reasons Novo Nordisk's management has chosen to accept the fine to avoid a lengthy lawsuit. This will finally settle the case.

Novo Nordisk A/S Reports Earnings Results for the First Six Months of 2014; Provides Earnings Guidance for the Year 2014

Novo Nordisk A/S reported earnings results for the first six months of 2014. For the period, the company reported sales increased by 7% in local currencies and by 1% in Danish kroner to DKK 42.0 billion compared to the same period in 2013. Operating profit increased by 12% in local currencies and by 4% in Danish kroner to DKK 16.8 billion. Net profit increased by 6% to DKK 13.5 billion. Diluted earnings per share increased by 9% to DKK 5.09. Net financial showed a net income of DKK 524 million compared to a net income of DKK 303 million in 2013. For the year 2014, sales growth measured in local currencies is still expected to be 7%-10% and operating profit growth measured in local currencies is still expected at around 10%. Operating profit growth is still expected to be around 10% measured in local currencies. The R&D ratio for 2014 is still expected to be in the range of 15% to 16% of sales. The company expects the net financial income of around DKK 300 million. This primarily reflects gains associated with foreign exchange hedging contracts following the depreciation of the U.S. dollar and the Japanese yen versus the Danish kroner compared to the average prevailing rates in 2013. The effective tax rate for 2014 is still expected to be around 22%. Capital expenditure is still expected to be around DKK 4 billion in 2014, primarily related to investments in additional GLP-1 manufacturing capacity, expansion of filling capacity, pre-filled device production facilities, as well as expansion of protein capacity for clinical trials supply. Depreciation, amortization and impairment are now expected to be around DKK 3 billion. The free cash flow for 2014 is still expected to be around DKK 25 billion.

Novo Nordisk A/S, Q2 2014 Earnings Call, Aug 08, 2014

Novo Nordisk A/S, Q2 2014 Earnings Call, Aug 08, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVO:US $45.69 USD +0.45

NVO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $55.06 USD -0.23
Amgen Inc $132.68 USD -0.34
Biogen Idec Inc $342.58 USD -3.26
Bristol-Myers Squibb Co $50.04 USD -0.26
Reckitt Benckiser Group PLC 5,240 GBp 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation NVO Industry Range
Price/Earnings 25.1x
Price/Sales 7.6x
Price/Book 17.6x
Price/Cash Flow 20.0x
TEV/Sales 6.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVO-NORDISK A/S-SPONS ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at